col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


58 Results       Page 1

 [1] 
Elsevier: Drug Discovery Today
  original article Date Title Authors   All Authors
1 [GO] 2023―Nov―28 Targeted degrader technologies as prospective SARS-CoV-2 therapies Rabia Khurshid, Joseph M. Schulz, Jiaming Hu, Timothy S. Snowden, Robert C. Reynolds, Stephan C. Schürer
2 [GO] 2023―Nov―16 Targeting SARS-CoV-2 nonstructural protein 3: function, structure, inhibition, and perspective in drug discovery Xin Li, Yongcheng Song
3 [GO] 2023―Sep―01 Deadly interactions: synergistic manipulations of concurrent pathogen infections potentially enabling future pandemics Kevin Roe
4 [GO] 2023―Jul―28 Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery Liang Xu, Ru Chen, Jie Liu, Tucker A Patterson, Huixiao Hong
5 [GO] 2023―Jul―22 Learning from COVID-19: How drug hunters can prepare for the next pandemic Ana C. Puhl, Thomas Lane, Sean Ekins
6 [GO] 2023―Jun―12 Harnessing aptamers against COVID-19: a therapeutic strategy Ali Mahmoudi, Seyedeh Hoda Alavizadeh, Seyedeh Atefeh Hosseini, Pouria Meidany, Maham Doagooyan, Yasaman Abolhasani, et al. (+5)
7 [GO] 2023―Apr―05 COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease Thales Kronenberger, Stefan A. Laufer, Thanigaimalai Pillaiyar
8 [GO] 2022―Sep―06 COVID-19 and fibrosis: mechanisms, clinical relevance, and future perspectives Mohd Aslam Saifi, Sapana Bansod, Chandraiah Godugu
9 [GO] 2022―Aug―19 The current status of COVID-19 vaccines. a scoping review Manuel Rueda-Fernández, Lucía Melguizo-Rodríguez, Víctor J. Costela-Ruiz, Anabel González-Acedo, Javier Ramos-Torrecillas, Rebeca Illescas-Montes
10 [GO] 2022―Jul―28 Nanosponges: an overlooked promising strategy to combat SARS-CoV-2 Ebrahim Mostafavi, Siavash Iravani, Rajender S. Varma
11 [GO] 2022―Jul―26 Impact of COVID-19 on male urogenital health: success of vaccines Kutay Kucukyildiz, Didem Yilmaz-Oral, Damla Turkcan, Cetin Volkan Oztekin, Serap Gur
12 [GO] 2022―Jul―04 Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein Saroj Verma, Vaishali M. Patil, Manish K. Gupta
13 [GO] 2022―Apr―06 Repurposing drugs as COVID-19 therapies: a toxicity evaluation Deborah K. Ngan, Tuan Xu, Menghang Xia, Wei Zheng, Ruili Huang
14 [GO] 2022―Feb―19 Efficacy of repurposed antiviral drugs: lessons from COVID-19 Miguel Angel Martinez
15 [GO] 2022―Feb―10 Drug repurposing against SARS-CoV-2 using computational approaches Sumit Kumar, Svitlana Kovalenko, Shakshi Bhardwaj, Aaftaab Sethi, Nikolay Yu. Gorobets, Sergey M. Desenko, Brijesh Rathi
16 [GO] 2021―Dec―23 Organoid and microfluidics-based platforms for drug screening in COVID-19 Roya Ramezankhani, Roya Solhi, Yoke Chin Chai, Massoud Vosough, Catherine Verfaillie
17 [GO] 2021―Dec―23 Applications of density functional theory in COVID-19 drug modeling Naike Ye, Zekai Yang, Yuchen Liu
18 [GO] 2021―Dec―11 Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs Rosemarie Bernabe, Cristina Torres, Grace Wangge, Edlyn Jimenez, Juntra Karbwang
19 [GO] 2021―Nov―08 The PI3K/Akt/mTOR pathway: a potential pharmacological target in COVID-19 Maria Sofia Basile, Eugenio Cavalli, James McCubrey, Jorge Hernández-Bello, José Francisco Muñoz-Valle, Paolo Fagone, Ferdinando Nicoletti
20 [GO] 2021―Oct―29 Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling Gajjela Bharath Kumar, Ming-Ming Zhou
21 [GO] 2021―Oct―19 Integrating heterogeneous data to facilitate COVID-19 drug repurposing Lucía Prieto Santamaría, Marina Díaz Uzquiano, Esther Ugarte Carro, Nieves Ortiz-Roldán, Yuliana Pérez Gallardo, Alejandro Rodríguez-González
22 [GO] 2021―Jul―30 Advances in the computational landscape for repurposed drugs against COVID-19 Illya Aronskyy, Yosef Masoudi-Sobhanzadeh, Antonio Cappuccio, Elena Zaslavsky
23 [GO] 2021―Jul―29 Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management Vivek P. Chavda, Lalitkumar K. Vora, Anjali K. Pandya, Vandana B. Patravale
24 [GO] 2021―Jul―28 Harnessing the power of microphysiological systems for COVID-19 research Nicole Kleinstreuer, Anthony Holmes
25 [GO] 2021―Jun―18 Recent progress on rapid SARS-CoV-2/COVID-19 detection by CRISPR-Cas13-based platforms Guillermo Aquino-Jarquin
26 [GO] 2021―May―25 High-throughput screening assays for SARS-CoV-2 drug development: current status and future directions Tuan Xu, Wei Zheng, Ruili Huang
27 [GO] 2021―Apr―29 Revamping the Ever-changing Landscape of Drug Development Processes in the Midst of COVID-19 Pandemic Charles Oo, Barbara Ameer
28 [GO] 2021―Apr―21 Web resources facilitate drug discovery in treatment of COVID-19 Long-Can Mei, Yin Jin, Zheng Wang, Ge-Fei Hao, Guang-Fu Yang
29 [GO] 2021―Apr―21 The impact of COVID-19 on the cell and gene therapies industry: disruptions, opportunities, and future prospects Tingting Qiu, Yitong Wang, Shuyao Liang, Ru Han, Mondher Toumi
30 [GO] 2021―Apr―16 The fight against COVID-19: striking a balance in the renin-angiotensin system Alexis Q. Dean, William P. Bozza, Julianne D. Twomey, Shen Luo, Ancy Nalli, Baolin Zhang
31 [GO] 2021―Mar―26 Diabetes, inflammation, and the adiponectin paradox: therapeutic targets in SARS-CoV-2 Gilbert Ho, Alysha Ali, Yoshiki Takamatsu, Ryoko Wada, Eliezer Masliah, Makoto Hashimoto
32 [GO] 2021―Feb―21 Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition? Mary EW Collier, Shaowei Zhang, Nigel S Scrutton, Flaviano Giorgini
33 [GO] 2021―Feb―18 Developing new drugs that activate the protective arm of the renin angiotensin system as a potential treatment for respiratory failure in COVID-19 patients Mathilde Latil, Serge Camelo, Stanislas Veillet, René Lafont, Pierre J. Dilda
34 [GO] 2021―Jan―23 SARS-CoV-2-mediated hyperferritinemia and cardiac arrest: preliminary insights Prakash VasanthiDharmalingam, Vengadeshprabhu Karuppagounder, Kenichi Watanabe, Harry Karmouty-Quintana, Suresh S. Palaniyandi, Ashrith Guha, Rajarajan A. Thandavarayan
35 [GO] 2021―Jan―22 Drugs acting on the renin-angiotensin system and SARS-CoV-2 A. Vitiello, C. Pelliccia, Francesco Ferrara
36 [GO] 2021―Jan―14 Modelling the World - can deliberately infecting healthy volunteers really tell us much about what happens outside the clinic during an epidemic or pandemic? Adrian Wildfire
37 [GO] 2020―Dec―09 Potential SARS-CoV-2 main protease inhibitors Riddhidev Banerjee, Lalith Perera, L.M. Viranga Tillekeratne
38 [GO] 2020―Nov―27 Expanded Access Programs, compassionate drug Use, and Emergency Use Authorizations during the COVID-19 pandemic John G. Rizk, Donald N. Forthal, Kamyar Kalantar-Zadeh, Mandeep R. Mehra, Carl J. Lavie, Youssef Rizk, et al. (+2)
39 [GO] 2020―Oct―27 Union is strength: antiviral and anti-inflammatory drugs for COVID-19 J. Jesús Naveja, Abraham Madariaga-Mazón, Francisco Flores-Murrieta, Julio Granados-Montiel, Marco Maradiaga-Ceceña, Víctor Duarte Alaniz, et al. (+4)
40 [GO] 2020―Oct―06 Virus-, host-, immune-based targets for COVID-19 therapy Wei Liu, Hai-Liang Zhu, Yongtao Duan
41 [GO] 2020―Sep―16 Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms Nitesh Sanghai, Geoffrey K. Tranmer
42 [GO] 2020―Sep―01 Could PROTACs Protect Us From COVID-19? Wilnelly Martinez-Ortiz, Ming-Ming Zhou
43 [GO] 2020―Aug―12 Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites Sally El Kantar, Bilal Nehmeh, Philippe Saad, Gabie Mitri, Celine Estephan, Mohamad Mroueh, et al. (+2)
44 [GO] 2020―Aug―07 Global clinical trial mobilization for COVID-19: higher, faster, stronger Reed F. Beall, Aidan Hollis
45 [GO] 2020―Jul―04 Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges Raymond Chang, Wei-Zen Sun
46 [GO] 2020―Jun―25 Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders Bruno O. Villoutreix, Philippe H. Beaune, Ryad Tamouza, Rajogapal Krishnamoorthy, Marion Leboyer
47 [GO] 2020―Jun―24 Emerging vaccine delivery systems for COVID-19 Nigel Theobald
48 [GO] 2020―Jun―24 Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19 Rajendran J.C. Bose, Jason R. McCarthy
49 [GO] 2020―Jun―20 Current and future therapeutical approaches for COVID-19 Yongtao Duan, Yongfang Yao, Senthil Arun Kumar, Hai-Liang Zhu, Junbiao Chang
50 [GO] 2020―Jun―20 Discovering small-molecule therapeutics against SARS-CoV-2 Vaibhav Tiwari, Jacob C. Beer, Nehru Viji Sankaranarayanan, Michelle Swanson-Mungerson, Umesh R. Desai
51 [GO] 2020―Jun―18 COVID-19 and pneumonia: a role for the uPA/uPAR system Daniele D’Alonzo, Maria De Fenza, Vincenzo Pavone
52 [GO] 2020―May―13 Shotgun drug repurposing biotechnology to tackle epidemics and pandemics William Mangione, Zackary Falls, Thomas Melendy, Gaurav Chopra, Ram Samudrala
53 [GO] 2020―May―06 Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment Lorraine O’Driscoll
54 [GO] 2020―May―01 Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19 Ilaria D’Acquarica, Israel Agranat
55 [GO] 2020―Apr―19 Déjà vu: Stimulating open drug discovery for SARS-CoV-2 Sean Ekins, Melina Mottin, Paulo R.P.S. Ramos, Bruna K.P. Sousa, Bruno Junior Neves, Daniel H. Foil, et al. (+6)
56 [GO] 2020―Apr―15 Boosting the arsenal against COVID-19 through computational drug repurposing Gennaro Ciliberto, Luca Cardone
57 [GO] 2020―Mar―18 Advance of promising targets and agents against 2019-nCoV in China Yongtao Duan, Hai-Liang Zhu, Chongchen Zhou
58 [GO] 2020―Jan―30 Recent discovery and development of inhibitors targeting coronaviruses Thanigaimalai Pillaiyar, Sangeetha Meenakshisundaram, Manoj Manickam
 [1] 

58 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec